[.
]Action/Kinetics:
Produces direct stimulation of both alpha-(pronounced) and beta-adrenergic receptors, as well as indirect stimulation through release of norepinephrine from storage sites. Results in decongestant effect on the nasal mucosa. Systemic administration eliminates possible damage to the nasal mucosa. Onset: 15-30 min. Time to peak effect: 30-60 min. Duration: 3-4 hr. Extended-release: duration, 8-12 hr. Urinary excretion slowed by alkalinization, causing reabsorption of drug.
Uses:
Nasal congestion associated with sinus conditions, otitis, allergies. Relief of eustachian tube congestion.
Additional Contraindications:
Lactation. Use of sustained-release products in children less than 12 years of age.
Special Concerns:
Use with caution in newborn and premature infants due to a higher risk of side effects. Geriatric clients may be more prone to age-related prostatic hypertrophy.
How Supplied:
Pseudoephedrine hydrochloride: Liquid: 7.5 mg/0.8 mL, 30 mg/5 mL; Syrup: 15 mg/5 mL, 30 mg/5 mL; Tablet: 30 mg, 60 mg; Tablet, extended release: 120 mg, 240 mg. Pseudoephedrine sulfate: Tablet: 60 mg
Dosage
Hydrochloride
•Oral Solution, Syrup, Tablets
Decongestant.
Adults: 60 mg q 4-6 hr, not to exceed 240 mg in 24 hr. Pediatric, 6-12 years: 30 mg using the oral solution or syrup q 4-6 hr, not to exceed 120 mg in 24 hr; 2-6 years: 15 mg using the oral solution or syrup q 4-6 hr, not to exceed 60 mg in 24 hr. Individualize the dose for children less than 2 years of age.
•Extended-Release Capsules, Tablets
Decongestant.
Adults and children over 12 years: 120 mg q 12 hr or 240 mg q 24 hr. Use is not recommended for children less than 12 years of age.
Sulfate
•Extended-Release Tablets
Decongestant.
Adults and children over 12 years: 120 mg q 12 hr. Use is not recommended for children less than 12 years of age.
Discuss prescriptions and health topics in the new 
